June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Repeatability and reproducibility of optic nerve head optical coherence tomography angiography (OCTA) measurements on glaucomatous and normal eyes
Author Affiliations & Notes
  • Lung Di
    Carl Zeiss Meditec, Inc., Dublin, California, United States
  • Sophia Yu
    Carl Zeiss Meditec, Inc., Dublin, California, United States
  • Patricia Sha
    Carl Zeiss Meditec, Inc., Dublin, California, United States
  • Todd Severin
    East Bay Eye Center, San Ramon, California, United States
  • Footnotes
    Commercial Relationships   Lung Di Carl Zeiss Meditec, Inc., Dublin, CA, United States., Code C (Consultant/Contractor); Sophia Yu Carl Zeiss Meditec, Inc., Dublin, CA, United States., Code E (Employment); Patricia Sha Carl Zeiss Meditec, Inc., Dublin, CA, United States., Code E (Employment); Todd Severin East Bay Eye Center, Code C (Consultant/Contractor)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 2944 – F0097. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Lung Di, Sophia Yu, Patricia Sha, Todd Severin; Repeatability and reproducibility of optic nerve head optical coherence tomography angiography (OCTA) measurements on glaucomatous and normal eyes. Invest. Ophthalmol. Vis. Sci. 2022;63(7):2944 – F0097.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The purpose of this study was to determine the repeatability and reproducibility (R&R) of spectral domain OCTA metrics on optic nerve OCTA en face images in normal and glaucomatous eyes.

Methods : Subjects with glaucoma and healthy controls (both >18 years old) were recruited in this study. If two eyes were eligible, one eye per subject was randomly designated as the study eye. Each eye was imaged using the Angiography 4.5x4.5 mm scan centered on the optic disc on CIRRUS™ HD-OCT 5000 with AngioPlex® OCT Angiography (ZEISS, Dublin, CA). Scans were repeated on 3 devices (by 3 different technicians) 3 times in 1 visit.

Data was processed on the AngioPlex Metrix in CIRRUS 11.0 software, which quantifies the density of vasculature. Two measures of blood vessels were used: Perfusion Density (PD), the area of blood vessels, and Flux Index (FI), the weighted intensity of the perfused vessels per unit area. PD is defined as the total area of perfused microvasculature per unit area, and ranges from 0 (no perfusion) to 1 (fully perfused). FI is defined as total weighted area of perfused microvasculature per unit area in a region of measurement. The weight is the normalized flow intensity corresponding to each pixel. Each scan is segmented into 4 sectors (temporal, nasal, superior, and inferior) for analysis, and a mean coefficient of variance (CV%) is calculated for both R&R. All statistics are estimated from two-way random-effect ANOVA model with random effects operator/device, eye and interaction between operator/device and eye.

Results : 22 control eyes (mean age 44.7 years, SD 14.7) and 21 glaucoma eyes (mean age 68.5 years, SD 8.9) were imaged. Table 1 and Table 2 shows FI and PD mean, standard deviation (both R&R), and coefficient of variance (CV%) for normal and glaucomatous eyes. Across all sectors, R&R CV% are below 5% in normal eyes, and no more than 6.1% in diseased eyes. Mean R&R CV% (both FI and PD) are less than 3% for normal eyes, and they are less than 5% for glaucomatous eyes.

Conclusions : All CV% (FI and PD) for normal and glaucomatous eyes are excellent, and no significant CV% difference is observed across all sectors from the scans. Given the R&R results, these parameters may be useful for monitoring disease progression or early detection of diseases. Future studies are needed to determine the clinical utility of these measurements.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×